The European Commission has approved Roche’s innovator rituximab, sold in Europe as MabThera, for the treatment of pemphigus vulgaris (PV), a rare autoimmune disorder. The approval marks the first biologic approval for PV in the European Union, and the first major new therapeutic option in 60 years.
The European Commission has approved Roche’s innovator rituximab, sold in Europe as MabThera, for the treatment of pemphigus vulgaris (PV), a rare autoimmune disorder. The approval marks the first biologic approval for PV in the European Union, and the first major new therapeutic option in 60 years.
PV is a blistering disease that occurs within the epidermis, affecting the skin and the mucous membranes. The condition is progressive, and can lead to life-threatening fluid loss, infection, and death.
“We’re pleased to bring the first biologic medicine to the more than 50,000 people in Europe suffering from pemphigus vulgaris,” says Sandra Horning, MD, Roche’s chief medical officer and head of global product development, in a statement. “This MabThera approval provides a much-needed new treatment that has been shown to provide higher remission rates than corticosteroids alone, which can cause debilitating side effects.”
The approval was based on phase 3 data from the Ritux 3 trial, which evaluated rituximab plus a tapering regimen of corticosteroids versus a standard dose of steroids alone as first-line treatment in 90 new patients with PV. In total, 89.5% of patients treated with rituximab plus steroids achieved complete steroid-free remission for 2 months or more, while only 27.8% of patients receiving steroids alone did so.
Currently, the phase 3, multicenter, randomized, double-blind PEMPHIX study is evaluating the safety and efficacy of rituximab versus the immunosuppressant mycophenolate mofetil.
The approval is not only positive news for European patients but also for Roche; according to Roche’s 2018 finance report, sales of MabThera have been declining since the advent of biosimilar rituximab in 2017. In Europe, sales dropped by 47% in 2018 versus 2017 as the branded drug fought for market share with 2 biosimilars.
In the United States, the FDA approved rituximab for the treatment of PV in 2018. The drug, sold in the United States as Rituxan, does not yet face a marketed biosimilar challenger, and the sole FDA-approved rituximab biosimilar, Truxima, sought only indications in oncology due to patent expiry considerations.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.